AstraZeneca has begun enrolling adults for a US-funded, 30,000-subject late-stage study of its high profile COVID-19 vaccine candidate.
Trial participants will receive either two doses of the experimental vaccine, dubbed AZD1222, four weeks apart, or a placebo, the company said on Monday.
Should the trials prove successful, Australians may be in line to receive the AstraZeneca vaccine.
The trial is being conducted under the US government’s Operation Warp Speed program.
The program aims to accelerate development, manufacturing and distribution of vaccines and treatments for COVID-19.
President Donald Trump has said a vaccine could be available before the November 3 presidential election, much sooner than experts anticipate.
AstraZeneca, which is developing its vaccine in conjunction with Oxford University researchers, and Pfizer Inc with partner BioNTech SE, have said they could have data by October to support US emergency use authorisation or approval of their respective vaccines.
Australia has signed a letter of intent with AstraZeneca and Oxford University to manufacture and distribute a vaccine, should the trials prove successful.
AZD1222 is already undergoing late-stage clinical trials in Britain, Brazil and South Africa.
Additional trials are planned in Japan and Russia.
The trials, together with the US Phase III study, aim to enrol up to 50,000 participants globally.
https://news.google.com/__i/rss/rd/articles/CBMijgFodHRwczovLzduZXdzLmNvbS5hdS9saWZlc3R5bGUvaGVhbHRoLXdlbGxiZWluZy9hc3RyYXplbmVjYS1iZWdpbnMtZW5yb2xsaW5nLWFkdWx0cy1pbi10aGUtdXMtZm9yLWl0cy1wb3RlbnRpYWwtY29yb25hdmlydXMtdmFjY2luZS0tYy0xMjgyMTEz0gGSAWh0dHBzOi8vN25ld3MuY29tLmF1L2xpZmVzdHlsZS9oZWFsdGgtd2VsbGJlaW5nL2FzdHJhemVuZWNhLWJlZ2lucy1lbnJvbGxpbmctYWR1bHRzLWluLXRoZS11cy1mb3ItaXRzLXBvdGVudGlhbC1jb3JvbmF2aXJ1cy12YWNjaW5lLS1jLTEyODIxMTMuYW1w?oc=5
2020-09-01 00:47:07Z
52781033696541
Bagikan Berita Ini
0 Response to "Coronavirus vaccine by AstraZeneca begins late-stage US study - 7NEWS.com.au"
Post a Comment